个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共14条记录   Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine [作者：Muggia, F; Diaz, I; Peters, GJ,期刊：Expert opinion on investigational drugs, 页码：403-408 , 文章类型： Editorial Material，,卷期：2012年21-4] Nucleoside analogs are widely used for treatment of various malignancies. Benchmark drugs are cytarabine for acute myeloid leukemia and gemcitabine for pancreatic and lung cancer. Sapacitabine is a novel cytidine analog ... Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia [作者：Balakrishnan, K; Gandhi, V,期刊：Expert opinion on investigational drugs, 页码：409-423 , 文章类型： Review，,卷期：2012年21-4] Introduction: Although protein kinases are primary targets for inhibition in hematological malignancies, until recently their contribution to chronic lymphocytic leukemia (CLL) was poorly understood. Insights into B-cell... PIM1 kinase as a target for cancer therapy [作者：Merkel, AL; Meggers, E; Ocker, M,期刊：Expert opinion on investigational drugs, 页码：425-436 , 文章类型： Review，,卷期：2012年21-4] Introduction: Inhibition of protein kinases has become a standard of modern clinical oncology. PIM1 belongs to a novel class of serine/threonine kinases with distinct molecular and biochemical features regulating various... Pemetrexed disodium in ovarian cancer treatment [作者：Morotti, M; Menada, MV; Venturini, PL; Mammoliti, S; Ferrero, S,期刊：Expert opinion on investigational drugs, 页码：437-449 , 文章类型： Review，,卷期：2012年21-4] Introduction: Current therapies for recurrent ovarian cancer (OC) yield relatively modest improvements in survival. Many drugs are available but recently a renewed interest is addressed on antimetabolite drugs. Pemetrexe... Novel targets for VEGF-independent anti-angiogenic drugs [作者：Petrillo, M; Scambia, G; Ferrandina, G,期刊：Expert opinion on investigational drugs, 页码：451-472 , 文章类型： Review，,卷期：2012年21-4] Introduction: In the last decades, the active research in the field of tumor angiogenesis led to the development of a class of agents providing an effective inhibition of neovessels formation through the blockade of VEGF... Current investigational drugs in psoriasis [作者：Ryan, C; Abramson, A; Patel, M; Menter, A,期刊：Expert opinion on investigational drugs, 页码：473-487 , 文章类型： Review，,卷期：2012年21-4] Introduction: The advent of biologic therapies has revolutionized the treatment of psoriasis. Increased understanding of immunogenetic pathways has allowed for the development of more selective targeted biologic therapie... Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS [作者：Uckun, FM; Cahn, P; Qazi, S; D'Cruz, O,期刊：Expert opinion on investigational drugs, 页码：489-500 , 文章类型： Review，,卷期：2012年21-4] Introduction: Pre-exposure prophylaxis (PrEP) is an evolving new approach to prevention of sexually transmitted HIV-1 that employs antiretroviral (ARV) agents prior to potential HIV-1 exposure in an attempt to reduce the... Angiotensin II type 2 receptor agonists: where should they be applied? [作者：Verdonk, K; Danser, AHJ; van Esch, JHM,期刊：Expert opinion on investigational drugs, 页码：501-513 , 文章类型： Review，,卷期：2012年21-4] Introduction: Angiotensin II, the active endproduct of the renin-angiotensin system (RAS), exerts its effects via angiotensin II type 1 and type 2 (AT(1), AT(2)) receptors. AT(1) receptors mediate all well-known effects ... Tedizolid (TR-701): a new oxazolidinone with enhanced potency [作者：Kanafani, ZA; Corey, GR,期刊：Expert opinion on investigational drugs, 页码：515-522 , 文章类型： Editorial Material，,卷期：2012年21-4] Introduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity ag... Dolutegravir for the treatment of HIV [作者：Katlama, C; Murphy, R,期刊：Expert opinion on investigational drugs, 页码：523-530 , 文章类型： Editorial Material，,卷期：2012年21-4] Introduction: Development of new antiretroviral drugs which are highly potent, tolerable over the long term and with a high genetic barrier to resistance is essential for the treatment of a chronic viral disease that req... Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma [作者：Patel, SP; Kim, KB,期刊：Expert opinion on investigational drugs, 页码：531-539 , 文章类型： Editorial Material，,卷期：2012年21-4] Introduction: Melanoma is the fifth most common cancer in men and seventh most common in women in the USA, and prognosis for patients with advanced melanoma is poor. The mitogen-activated protein (MAP) kinase signaling p... Sapacitabine for cancer [作者：Liu, XJ; Kantarjian, H; Plunkett, W,期刊：Expert opinion on investigational drugs, 页码：541-555 , 文章类型： Editorial Material，,卷期：2012年21-4] Introduction: Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic malignancies and solid tumors. The active metabolite of sapacitabine, CNDAC (2'-C-cyano-2'-deoxy-1... Sorafenib in melanoma [作者：Mangana, J; Levesque, MP; Karpova, MB; Dummer, R,期刊：Expert opinion on investigational drugs, 页码：557-568 , 文章类型： Editorial Material，,卷期：2012年21-4] Introduction: Sorafenib is an orally available multi-kinase inhibitor that inhibits tumor proliferation by targeting multiple kinases including the vascular endothelial growth factor receptors VEGFR1, VEGFR2, VEGFR3 and ... Dalcetrapib - restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease Evaluation of Fayad ZA, Mani V, Woodward M et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59 [作者：Doggrell, SA,期刊：Expert opinion on investigational drugs, 页码：569-573 , 文章类型： Editorial Material，,卷期：2012年21-4] Background: As lowHDL cholesterol levels are a risk factor for cardiovascular disease, raising HDL cholesterol substantially by inhibiting or modulating cholesteryl ester transfer protein (CETP) may be useful in coronary...